泰格医药(300347) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥1,660,204,321.44, a decrease of 8.00% compared to ¥1,804,571,375.28 in the same period last year[5] - Net profit attributable to shareholders was ¥235,072,002.70, down 58.65% from ¥568,455,092.87 year-on-year[5] - The basic and diluted earnings per share decreased by 59.09% to ¥0.27 from ¥0.66 in the same period last year[5] - The net profit for Q1 2024 was CNY 312,570,373.39, a decrease of 45.0% compared to CNY 568,325,660.27 in Q1 2023[24] - The operating profit for Q1 2024 was CNY 362,196,228.41, a decline of 42.6% from CNY 630,897,782.90 in Q1 2023[24] - The company reported a total comprehensive income of CNY 290,331,159.48 for Q1 2024, down from CNY 521,771,775.19 in Q1 2023[24] - The total revenue from operating activities was CNY 1,476,940,313.67, down 3.2% from CNY 1,525,588,216.35 in the previous year[26] Cash Flow - The net cash flow from operating activities increased significantly by 405.83%, reaching ¥144,204,460.07 compared to ¥28,508,219.40 in the previous year[9] - The cash flow from operating activities generated a net amount of CNY 144,204,460.07, significantly up from CNY 28,508,219.40 in the same period last year[26] - The cash flow from investing activities showed a net outflow of CNY 119,716,564.11, an improvement from a net outflow of CNY 547,512,821.57 in the previous year[26] - The cash flow from financing activities generated a net inflow of CNY 2,424,771.97, a significant decrease from CNY 302,161,242.23 in Q1 2023[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥30,070,185,491.17, reflecting a 1.31% increase from ¥29,680,742,349.17 at the end of the previous year[5] - The total assets as of March 31, 2024, amounted to CNY 30,070,185,491.17, up from CNY 29,680,742,349.17 at the beginning of the year[22] - The total liabilities increased to CNY 5,536,893,616.67 from CNY 5,227,180,203.91, indicating a rise in financial obligations[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 66,740[11] - The largest shareholder, Ye Xiaoping, holds 20.49% of shares, totaling 177,239,541 shares[11] - The second largest shareholder, HKSCC NOMINEES LIMITED, holds 14.23% of shares, totaling 123,116,179 shares[11] - The top 10 shareholders account for a significant portion of the company's equity, with the top three alone holding over 40%[11] - The company has no preferred shareholders as indicated by the absence of any in the report[16] Investment and Income - The company reported a significant decrease in investment income, down 113.93% to -¥3,591,151.18 from ¥25,784,682.29 year-on-year[8] - The fair value change income dropped by 92.77% to ¥12,753,272.78 compared to ¥176,412,728.63 in the previous year, primarily due to a decline in the stock prices of other non-current financial assets[8] - The company received government subsidies amounting to ¥12,209,543.65 during the reporting period, contributing to an increase in other income by 198.25%[8] Cost Management - Total operating costs for Q1 2024 were CNY 1,305,287,804.37, down from CNY 1,360,291,377.24, reflecting a cost reduction strategy[23] - Research and development expenses for Q1 2024 were CNY 63,906,152.52, slightly down from CNY 64,519,361.97, indicating a focus on cost management in R&D[23] Equity and Share Restrictions - The company’s equity attributable to shareholders increased to CNY 21,131,829,587.05 from CNY 21,026,774,725.75, reflecting a positive trend in shareholder value[22] - The total number of restricted shares held by Ye Xiaoping is 132,929,656, which is subject to a 25% annual release[17] - The total number of restricted shares held by Cao Xiaochun is 38,746,330, also subject to a 25% annual release[17] - The company has a total of 171,687,044 restricted shares across all shareholders[17] - There were no changes in the number of restricted shares during the reporting period[17] - The report indicates no participation in margin financing by the top shareholders[12] Future Outlook - The company plans to continue exploring market expansion opportunities and new product development as part of its growth strategy[19]